Eupraxia Pharmaceuticals (EPRX) Competitors $3.56 -0.38 (-9.64%) As of 10:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EPRX vs. PGEN, KALV, CGEM, AUTL, RAPP, RNAC, TRDA, ABVX, MAZE, and MLYSShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Precigen (PGEN), KalVista Pharmaceuticals (KALV), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Entrada Therapeutics (TRDA), ABIVAX Société Anonyme (ABVX), Maze Therapeutics (MAZE), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Precigen KalVista Pharmaceuticals Cullinan Therapeutics Autolus Therapeutics Rapport Therapeutics Cartesian Therapeutics Entrada Therapeutics ABIVAX Société Anonyme Maze Therapeutics Mineralys Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Do analysts rate EPRX or PGEN? Eupraxia Pharmaceuticals presently has a consensus target price of $10.50, indicating a potential upside of 166.50%. Precigen has a consensus target price of $7.00, indicating a potential upside of 319.16%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Precigen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community believe in EPRX or PGEN? Precigen received 432 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 67.39% of users gave Precigen an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesPrecigenOutperform Votes43667.39% Underperform Votes21132.61% Do insiders & institutionals have more ownership in EPRX or PGEN? 33.5% of Precigen shares are held by institutional investors. 44.9% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to EPRX or PGEN? In the previous week, Precigen had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 7 mentions for Precigen and 4 mentions for Eupraxia Pharmaceuticals. Precigen's average media sentiment score of 0.94 beat Eupraxia Pharmaceuticals' score of 0.38 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EPRX or PGEN more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Precigen -3,521.68%-123.06%-87.33% Which has preferable earnings and valuation, EPRX or PGEN? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Precigen. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.72-5.47Precigen$3.96M123.41-$95.90M-$0.55-3.04 SummaryPrecigen beats Eupraxia Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.45M$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-5.476.1524.9519.25Price / SalesN/A187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book131.336.447.334.28Net Income-$28.22M$139.03M$3.18B$247.04M7 Day Performance-5.06%-3.50%-2.89%-3.25%1 Month Performance27.92%-9.22%-6.79%-6.55%1 Year PerformanceN/A-12.95%12.28%4.01% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.4909 of 5 stars$3.56-9.6%$10.50+194.9%N/A$126.90MN/A-4.9429Gap DownPGENPrecigen3.8766 of 5 stars$1.75-8.4%$7.00+300.0%-1.2%$512.52M$3.96M-3.18190KALVKalVista Pharmaceuticals4.7208 of 5 stars$10.35+3.2%$23.80+130.0%-23.1%$511.48MN/A-2.84100Upcoming EarningsShort Interest ↓High Trading VolumeCGEMCullinan Therapeutics1.9437 of 5 stars$8.72-3.4%$32.50+272.7%-56.8%$507.77MN/A-3.0730Earnings ReportAnalyst RevisionAUTLAutolus Therapeutics2.5681 of 5 stars$1.88-3.6%$10.40+453.2%-71.9%$500.26M$10.09M-1.55330RAPPRapport Therapeutics1.6697 of 5 stars$13.24+4.4%$35.00+164.4%N/A$484.32MN/A0.00N/AUpcoming EarningsNews CoverageGap DownHigh Trading VolumeRNACCartesian Therapeutics2.0149 of 5 stars$19.02-1.1%$42.86+125.3%-15.5%$483.39M$47.94M-0.3664Upcoming EarningsNews CoverageTRDAEntrada Therapeutics3.1538 of 5 stars$12.85-1.5%$25.67+99.7%-17.5%$480.85M$215.23M8.08110Earnings ReportAnalyst RevisionNews CoverageABVXABIVAX Société Anonyme2.4544 of 5 stars$7.49-7.3%$38.67+416.2%-47.4%$474.64MN/A0.0061Positive NewsGap DownMAZEMaze TherapeuticsN/A$10.82-10.5%N/AN/A$473.70MN/A0.00121MLYSMineralys Therapeutics3.0918 of 5 stars$9.25-3.2%$27.00+191.9%-41.7%$460.98MN/A-2.5428 Related Companies and Tools Related Companies Precigen Competitors KalVista Pharmaceuticals Competitors Cullinan Therapeutics Competitors Autolus Therapeutics Competitors Rapport Therapeutics Competitors Cartesian Therapeutics Competitors Entrada Therapeutics Competitors ABIVAX Société Anonyme Competitors Maze Therapeutics Competitors Mineralys Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EPRX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
